UA97286C2 - Способ изготовления суспензии арипипразола и лиофилизированного состава - Google Patents

Способ изготовления суспензии арипипразола и лиофилизированного состава

Info

Publication number
UA97286C2
UA97286C2 UAA201002139A UAA201002139A UA97286C2 UA 97286 C2 UA97286 C2 UA 97286C2 UA A201002139 A UAA201002139 A UA A201002139A UA A201002139 A UAA201002139 A UA A201002139A UA 97286 C2 UA97286 C2 UA 97286C2
Authority
UA
Ukraine
Prior art keywords
suspension
manufacturing
aripiprazol
lyophilized composition
aripiprazole
Prior art date
Application number
UAA201002139A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Сього Хираока
Такакуни Матсуда
Джуничи Хатанака
Original Assignee
Оцука Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39816777&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA97286(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Оцука Фармасьютикал Ко., Лтд. filed Critical Оцука Фармасьютикал Ко., Лтд.
Publication of UA97286C2 publication Critical patent/UA97286C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
UAA201002139A 2007-07-31 2008-07-30 Способ изготовления суспензии арипипразола и лиофилизированного состава UA97286C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007200088 2007-07-31
PCT/JP2008/064076 WO2009017250A1 (en) 2007-07-31 2008-07-30 Methods for producing aripiprazole suspension and freeze-dried formulation

Publications (1)

Publication Number Publication Date
UA97286C2 true UA97286C2 (ru) 2012-01-25

Family

ID=39816777

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201002139A UA97286C2 (ru) 2007-07-31 2008-07-30 Способ изготовления суспензии арипипразола и лиофилизированного состава

Country Status (27)

Country Link
US (7) US9457026B2 (OSRAM)
EP (1) EP2170279B1 (OSRAM)
JP (1) JP4879349B2 (OSRAM)
KR (1) KR101546106B1 (OSRAM)
CN (1) CN101801342B (OSRAM)
AR (2) AR067747A1 (OSRAM)
CA (1) CA2695178C (OSRAM)
CO (1) CO6290634A2 (OSRAM)
CY (1) CY1120165T1 (OSRAM)
DK (1) DK2170279T3 (OSRAM)
ES (1) ES2661037T3 (OSRAM)
HR (1) HRP20180295T1 (OSRAM)
HU (1) HUE036214T2 (OSRAM)
IL (2) IL244186A0 (OSRAM)
LT (1) LT2170279T (OSRAM)
MX (1) MX2010001311A (OSRAM)
MY (1) MY152789A (OSRAM)
NO (1) NO2170279T3 (OSRAM)
NZ (1) NZ582415A (OSRAM)
PL (1) PL2170279T3 (OSRAM)
PT (1) PT2170279T (OSRAM)
RU (1) RU2483711C2 (OSRAM)
SI (1) SI2170279T1 (OSRAM)
TW (1) TWI410255B (OSRAM)
UA (1) UA97286C2 (OSRAM)
WO (1) WO2009017250A1 (OSRAM)
ZA (1) ZA201000307B (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010001311A (es) * 2007-07-31 2010-04-21 Otsuka Pharma Co Ltd Metodo para producir una suspensi?n de aripiprazol y formulacion liofilizada.
PT105058B (pt) 2010-04-21 2013-04-17 Hovione Farmaciencia S A Processo para processamento de partículas de ingredientes activos farmacêuticos
MX344235B (es) * 2010-08-24 2016-12-07 Otsuka Pharmaceutical Co Ltd * Suspension y composicion en torta que contiene un derivado de carbostirilo y aceite de silicona y/o un derivado de aceite de silicona.
DK2667856T3 (da) * 2011-01-24 2021-08-30 Otsuka Pharma Co Ltd Medicinsk indretning indeholdende en tørstofsammensætning omfattende aripiprazol som en aktiv ingrediens, og en tørstofsammensætning omfattende aripiprazol som en aktiv ingrediens
JO3410B1 (ar) * 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd تركيبة أريبيبرازول مجفف بالتبريد
KR101103011B1 (ko) * 2011-10-13 2012-01-05 (주)일신오토클레이브 스크루 형 고압 발생 장치
CN102524261B (zh) * 2011-12-16 2014-12-03 辽宁师范大学 一种强力生根剂纳米制剂、其制备方法及应用
CN102450269A (zh) * 2011-12-27 2012-05-16 辽宁师范大学 三唑酮纳米胶体悬浮剂及其制备方法
JOP20200109A1 (ar) * 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
AR090775A1 (es) 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
WO2014002553A1 (ja) * 2012-06-29 2014-01-03 丸石製薬株式会社 アリピプラゾールの経口医薬製剤
JP5341282B1 (ja) * 2012-06-29 2013-11-13 丸石製薬株式会社 アリピプラゾールの経口医薬製剤
JP6007169B2 (ja) * 2012-11-30 2016-10-12 大原薬品工業株式会社 アリピプラゾール無水物を含有する固形製剤の製造方法
US9655951B2 (en) * 2013-01-23 2017-05-23 Cartilast II LLC Preservation of the biological activity of undenatured type II collagen
AR096131A1 (es) 2013-04-30 2015-12-09 Otsuka Pharma Co Ltd Preparado oral sólido que comprende aripiprazol y un método para producir un preparado oral sólido que comprende aripiprazol
EP3233077A4 (en) 2014-12-19 2018-08-08 The Broad Institute Inc. Dopamine d2 receptor ligands
WO2017025930A1 (en) 2015-08-12 2017-02-16 Ftf Pharma Private Limited Oral solution of aripiprazole
CN106474058B (zh) 2015-08-31 2020-01-07 南京诺瑞特医药科技有限公司 具有延长的保质期的阿立哌唑可注射悬浮液制剂
CA3030972A1 (en) 2016-07-28 2018-02-01 Mylan Laboratories Ltd Process for preparing sterile aripiprazole formulation
US10821200B2 (en) 2016-12-05 2020-11-03 Hyalo Technologies, LLC Method of sterilization of microparticles
CN108938578A (zh) * 2017-05-25 2018-12-07 万全万特制药（厦门）有限公司 阿立哌唑分散片及其制备方法
WO2021199076A1 (en) * 2020-03-30 2021-10-07 Cipla Limited Injectable aripiprazole formulation
EP4043008A1 (en) 2021-02-15 2022-08-17 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Method for the preparation of a pharmaceutical composition comprising aripiprazole
CN115364049A (zh) * 2021-05-18 2022-11-22 苏州恩华生物医药科技有限公司 一种月桂酰阿立哌唑混悬剂的制备方法
CN115554253B (zh) * 2022-10-14 2024-03-29 浙江圣兆药物科技股份有限公司 一种平稳释药的注射用阿立哌唑冻干制剂及其制备方法
CN117281784B (zh) * 2023-11-24 2024-02-27 山东则正医药技术有限公司 一种阿立哌唑注射剂及其制备方法和应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB209551A (en) 1922-11-20 1924-01-17 William Mortimer Melmore Improvements in or relating to petrol and other cans
JPS54130587A (en) * 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
CA1209477A (en) 1981-03-26 1986-08-12 Bruce E. Haeger Composition of matter comprising a lyophilized preparation of a penicillin derivative
JPS5832899A (ja) 1981-08-18 1983-02-25 Takeda Chem Ind Ltd オキセンドロン水性懸濁剤
US4352811A (en) * 1981-11-12 1982-10-05 Hoechst-Roussel Pharmaceuticals Inc. 3-(1-Substituted-4-piperidyl)-1,2-benzisoxazoles
IL68549A (en) * 1983-05-03 1988-05-31 Kit Medidont Ltd Method and instrument for measuring moisture
KR850004274A (ko) * 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP2608788B2 (ja) 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
FR2663223B1 (fr) 1990-06-14 1994-12-02 Af Aplicaciones Far Lab Forme galenique parenterale.
JP3282731B2 (ja) * 1990-06-15 2002-05-20 メルク エンド カムパニー インコーポレーテッド 結晶の構造および大きさを改良する結晶化方法
IT1244880B (it) 1990-12-11 1994-09-12 Torre A Farmaceutici Formulazioni di amminoacidi liofilizzati contenenti glutammina, loro preparazione ed uso nell'alimentazione parenterale
US6193983B1 (en) * 1992-06-01 2001-02-27 The University Of Melbourne Equine herpesvirus glycoproteins
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
SK282231B6 (sk) * 1993-11-19 2001-12-03 Janssen Pharmaceutica N. V. Farmaceutický prostriedok na liečenie psychotických porúch
ES2194911T3 (es) 1994-06-02 2003-12-01 Elan Drug Delivery Ltd Metodo para evitar la agregacion de proteinas/peptidos cuando tiene lugar su rehidratacion o descongelacion.
RU2082401C1 (ru) 1994-08-18 1997-06-27 Фармацевтическое акционерное общество "Ферейн" Способ получения лекарственной формы комбинированного препарата
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US6165442A (en) * 1996-02-19 2000-12-26 Nycomed Imaging As Thermally stabilized ultrasound contrast agent
DE69725877T2 (de) 1996-08-26 2004-07-22 Transgene S.A. Kationische lipid-nukleinsäure komplexe
US6297231B1 (en) * 1996-10-28 2001-10-02 Merck & Co., Inc. Stabilized carbapenem antibiotic compositions and method of making
GB9705588D0 (en) * 1997-03-18 1997-05-07 Anglia Research Foundation Stable particle in liquid formulations
GB9718986D0 (en) 1997-09-09 1997-11-12 Danbiosyst Uk Controlled release microsphere delivery system
CA2326456C (en) 1998-03-30 2008-12-23 Rtp Pharma Inc. Composition and method of preparing microparticles of water-insoluble substances
DE69935433T2 (de) * 1998-07-30 2007-10-25 Point Biomedical Corp., San Carlos Neuer wirkstoffträger für die gefriertrocknung von wässrigen suspensionen von mikropartikeln
DE19857609A1 (de) * 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
US6455526B1 (en) * 1998-12-16 2002-09-24 Aventis Pharmaceuticals, Inc. Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same
US6267989B1 (en) * 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
EP1814532B1 (en) * 1999-05-27 2012-01-18 George F. El Khoury Topical application of muscarinic and opioid agents for treatment of tinnitus
JP2001187735A (ja) 2000-01-05 2001-07-10 Towa Yakuhin Kk 安定なニコランジル含有粉末の製造法
US6559128B1 (en) * 2000-01-21 2003-05-06 Northwestern University Inhibitors of G protein-mediated signaling, methods of making them, and uses thereof
RU2169574C1 (ru) 2000-01-27 2001-06-27 Кобатов Алексей Иванович Способ получения биопрепарата и сухой биопрепарат
AU2001233180A1 (en) 2000-02-10 2001-08-20 Alkermes Controlled Therapeutics, Inc. Method of preparing a sustained release composition
CN1245967C (zh) 2000-03-27 2006-03-22 斯克里普斯研究学院 化合物的制药用途
CN1313080C (zh) 2000-04-20 2007-05-02 斯凯伊药品加拿大公司 改进的水不溶性药物粒子的制备方法
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
JP2002241284A (ja) 2001-02-16 2002-08-28 Towa Yakuhin Kk 全身投与用アルガトロバン注射液
MY129350A (en) 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
JP2003063965A (ja) * 2001-06-13 2003-03-05 Otsuka Pharmaceut Factory Inc 注射用シロスタゾール水性製剤
MXPA03011538A (es) 2001-06-14 2004-03-09 Otsuka Pharma Co Ltd Composicion medicinal que sustancialmente no causaria dano a la mucosa intestinal.
DE60224293T2 (de) 2001-09-21 2008-12-11 Egalet A/S Feste dispersionen mit kontrollierter freisetzung von carvedilol
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
ITMI20020808A1 (it) * 2002-04-17 2003-10-17 Chiesi Farma Spa Procedimento per la preparazione di una sospensione sterile di particelle di beclometasone dipropionato da somministrare per inalazione
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
JP4776229B2 (ja) * 2002-07-16 2011-09-21 エラン ファーマ インターナショナル，リミティド 安定なナノ粒子活性物質の液体投与組成物
HRP20050149B1 (hr) * 2002-08-20 2014-09-12 Otsuka Pharmaceutical Co., Ltd. Formulacija aripiprazol kompleksa i postupak
ITMI20022674A1 (it) 2002-12-18 2004-06-19 Chiesi Farma Spa Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione.
MXPA05007158A (es) * 2002-12-31 2005-09-21 Nektar Therapeutics Formulacion farmaceutica con un agente activo insoluble.
WO2004064752A2 (en) 2003-01-22 2004-08-05 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
JP2005022989A (ja) 2003-06-30 2005-01-27 Otsuka Pharmaceut Factory Inc 可溶化または分散化された難溶性化合物を含む組成物
US6987111B2 (en) * 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
US20050032811A1 (en) 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
TWI371274B (en) 2003-10-23 2012-09-01 Bristol Myers Squibb Co Process for making sterile aripiprazole of desired mean particle size
JP4836797B2 (ja) * 2003-10-23 2011-12-14 大塚製薬株式会社 放出制御性無菌注射アリピプラゾール製剤および方法
CA2543296A1 (en) * 2003-10-31 2005-05-12 Point Biomedical Corporation Reconstitutable microsphere compositions useful as ultrasonic contrast agents
WO2005072702A2 (en) * 2004-01-20 2005-08-11 Alkermes Controlled Therapeutics, Inc. Method for milling frozen microparticles
WO2005089718A2 (en) * 2004-03-23 2005-09-29 Novartis Ag Pharmaceutical compositions
DE102005011786A1 (de) * 2005-03-11 2006-09-14 Pharmasol Gmbh Verfahren zur Herstellung ultrafeiner Submicron-Suspensionen
WO2006097343A1 (en) * 2005-03-17 2006-09-21 Synthon B.V. Process of making crystalline type ii aripiprazole
CA2622758A1 (en) 2005-09-15 2007-03-29 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
US9034381B2 (en) * 2005-11-10 2015-05-19 Alphapharm Pty Ltd Process to control particle size
US20070148245A1 (en) * 2005-12-22 2007-06-28 Ilan Zalit Compressed solid dosage forms with drugs of low solubility and process for making the same
MX2010001311A (es) * 2007-07-31 2010-04-21 Otsuka Pharma Co Ltd Metodo para producir una suspensi?n de aripiprazol y formulacion liofilizada.

Also Published As

Publication number Publication date
DK2170279T3 (en) 2018-03-12
US20180185358A1 (en) 2018-07-05
AR067747A1 (es) 2009-10-21
RU2009149820A (ru) 2011-09-10
CA2695178C (en) 2015-06-23
CN101801342B (zh) 2012-07-11
ES2661037T3 (es) 2018-03-27
RU2483711C2 (ru) 2013-06-10
US9457026B2 (en) 2016-10-04
CY1120165T1 (el) 2018-12-12
KR101546106B1 (ko) 2015-08-20
AU2008283251A1 (en) 2009-02-05
PT2170279T (pt) 2018-04-06
US20170035752A1 (en) 2017-02-09
US20200246333A1 (en) 2020-08-06
KR20100057020A (ko) 2010-05-28
NO2170279T3 (OSRAM) 2018-05-26
CN101801342A (zh) 2010-08-11
LT2170279T (lt) 2018-03-12
JP4879349B2 (ja) 2012-02-22
MY152789A (en) 2014-11-28
MX2010001311A (es) 2010-04-21
CA2695178A1 (en) 2009-02-05
TW200922636A (en) 2009-06-01
US20240139177A1 (en) 2024-05-02
CO6290634A2 (es) 2011-06-20
HRP20180295T1 (hr) 2018-03-23
SI2170279T1 (en) 2018-04-30
US20250302826A1 (en) 2025-10-02
NZ582415A (en) 2012-05-25
US20100196486A1 (en) 2010-08-05
JP2010535151A (ja) 2010-11-18
EP2170279B1 (en) 2017-12-27
WO2009017250A1 (en) 2009-02-05
HUE036214T2 (hu) 2018-06-28
IL244231A0 (en) 2016-04-21
TWI410255B (zh) 2013-10-01
AR117941A2 (es) 2021-09-08
ZA201000307B (en) 2011-04-28
BRPI0815382A2 (pt) 2015-02-10
IL244186A0 (en) 2016-04-21
EP2170279A1 (en) 2010-04-07
PL2170279T3 (pl) 2018-05-30
US20210361646A1 (en) 2021-11-25

Similar Documents

Publication Publication Date Title
UA97286C2 (ru) Способ изготовления суспензии арипипразола и лиофилизированного состава
MX2007000072A (es) Metodo para producir particulas ceramicas solidas utilizando un proceso de secado por pulverizacion.
EP2796469A3 (en) Novel compositions and methods for treating ige-mediated disorders
AR064997A1 (es) Un producto abrasivo recubierto, una suspension de abrasivo, un producto abrasivo aglutinado , un material particulado, un metodo para formar un material particulado abrasivo y un metodo para maquinar una pieza de trabajo
WO2011130516A3 (en) Method of making a diamond particle suspension and method of making a polycrystalline diamond article therefrom
EP4302955A3 (en) Shaped abrasive particles and methods of forming same
BRPI0815627A2 (pt) Material de revestimento, processo para a produção de um agente de revestimento, e, uso de um material de revestimento.
CL2011001419A1 (es) Procedimiento para separar por lo menos un primer material de una mezcla, que comprende contactar la mezcla con una sustancia de superficie activa, tratar la dispersión con partículas magnéticas hidrófobas para que formen aglomerados con el primer material y la sustancia, separar los aglomerados y disociar dichos aglomerados
UY34628A (es) ?material mineral en polvo con elevada capacidad de dispersión, y uso de dicho material mineral en polvo?.
MX2009013600A (es) Material de montaje reposicionable, dispositivo de control de contaminacion y metodos de elaboracion del mismo.
GB2457616A (en) Purification method
WO2011105865A3 (ko) 세퍼레이터의 제조방법, 이로부터 형성된 세퍼레이터 및 이를 포함하는 전기화학소자의 제조방법
CL2008002807A1 (es) Composición de resina curable que comprende una dispersión acuosa de metilol melamina con ph entre 8-10 y resina basada en formaldehído; producto abrasivo que comprende particulas abrasivas y aglomerante proveniente de la composición; procedimiento para prepararlos; procedimiento para amolar superficies.
BR112014001169A2 (pt) composição aglutinante para aglomeração de minerais finos e processo de peletização usando o mesmo
WO2012010395A3 (en) Alignment of graphite nanofibers in thermal interface material
WO2014093391A3 (en) Ceramic composition having dispersion of nano-particles therein and methods of fabricating same
EP3919616A4 (en) PARTICULATE AGGREGATE WITH CELL SUPPORT AND PROCESS FOR ITS MANUFACTURE
MX2019004304A (es) Composiciones acuosas de recubrimiento mate.
WO2022035888A3 (en) Sars-cov-2-neutralizing antibodies, biomarkers to predict protection from re-infection, and high efficiency antibody screening methods
NZ723631A (en) Nanosuspension of natural materials and preparation method thereof
DE60310964D1 (de) Zerkleinerungsverfahren für anorganisches partikelförmiges material
GB2539307A8 (en) Highly fluorescent diamond particles and methods of fabricating the same
TW200704750A (en) Functional organic particle, and method for preparing the same
TWI365170B (en) Chain inorganic oxide fine particle groups, process for preparing dispersion of the fine particle groups, and uses of the fine particle groups
WO2009102171A3 (en) Silica magnetic particles having a spherical form and a process for preparing the same